Loading…
Cerenome Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in CNSY.
▼ -99.7% over 5Y.
today you would have $2.78▼ -99.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 17 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $12.75 | $28.75 | $43.75 | $120.00 | $393.75 | $757.50 | $900.00 | $5,437.50 | $56,250.00 | $283,125.00 | $534,375.00 | $1,378,125.00 | $7,228,125.00 | $7,875,000.00 | $6,187,500.00 | $14,596,875.00 | $17,156,250.00 |
Seven formulas applied to what the company reported. None of them predicts a price — each answers what the stock would be worth if its assumption held. The assumption is printed next to every number, because it is the assumption that produces the result.
Square root of 22.5 × earnings × book value — the two ceilings Graham proposed. Blind to intangibles, so it undervalues software and brands.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| JSPRJasper Therapeutics, Inc. | $0.70 | — | 14.0x | — | -255.04% | $23.28M |
| MRKRMarker Therapeutics, Inc. | $1.37 | — | 1.9x | — | -76.87% | $22.84M |
| ENLVEnlivex Ltd. | $1.35 | 0.0x | 0.0x | — | 126.17% | $23.61M |
| BFRIBiofrontera Inc. | $1.59 |
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers, by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas, as well as develops a data analytics and artificial intelligence platform to integrate diverse data sets into actionable insights that support precision oncology, therapeutic development, and clinical decision-making. The company was formerly known as Plus Therapeutics, Inc. and changed its name to Cerenome, Inc. in August 2026. Cerenome, Inc. was founded in 1996 and is headquartered in Houston, Texas.
Company description provided by Yahoo Finance.
| P/S | 10.6x | 16.8x | 3.4x | 1.5x | — | — | — | — | 1.3x | 6.7x | 7.1x | 7.6x | 10.6x | 27.4x | 21.7x | 16.3x | 31.8x | 38.2x |
| P/B | 8.0x | 21.9x | — | — | 1.7x | 2.1x | 14.1x | 8.0x | 0.9x | 1.4x | 3.0x | 3.0x | — | 62.3x | 29.3x | 13.1x | 11.5x | — |
| EPS | -$7.25 | -$58.50 | -$106.00 | -$289.50 | -$416.25 | -$697.50 | -$3,101.25 | -$32,617.50 | -$154,312.50 | -$240,000.00 | -$388,125.00 | -$1,350,000.00 | -$1,096,875.00 | -$1,546,875.00 | -$1,715,625.00 | -$1,687,500.00 | -$1,828,125.00 |
| Profit margin | -387.43% | -429.43% | -222.84% | -271.04% | — | — | — | — | -344.16% | -843.66% | -473.50% | -387.43% | -754.45% | -367.55% | -370.64% | -406.50% | -333.10% | -397.74% |
| ROE | -271.89% | -560.21% | — | — | -314.58% | -123.65% | -271.89% | -938.53% | -241.80% | -174.51% | -200.67% | -153.56% | — | -835.79% | -500.06% | -326.27% | -120.20% | — |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Not the average of the seven numbers above. Four of the seven start from the same earnings per share — Graham, Lynch, sector multiples and its own history — so averaging all seven would let one input count four times and drown out the others. Instead each family produces one number, and the fair price is the average of the families that answered. A family with two working formulas contributes their average, not two votes.
1 methods answered, across 1 families.
Every formula reads the same reported statements and they can be wrong together. The margin is room for that.
+127.3% from the average.
These are models, not forecasts, and not investment advice. Change one assumption and the number changes with it — that is a property of valuation, not a defect of this page.
| — |
| 3.8x |
| — |
| -988.35% |
| $23.62M |
| NXTCNextCure, Inc. | $5.18 | — | 1.7x | — | -204.56% | $23.71M |
| ALLRAllarity Therapeutics, Inc. | $1.41 | — | 6.4x | — | -157.09% | $22.43M |